Cystic Fibrosis-related Liver Disease: The Next Challenge
Robert D Baker1, Susan S Baker
1Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, NY.
Journal of Pediatric Gastroenterology and Nutrition
|August 3, 2020
Summary
Cystic fibrosis-related liver disease (CFLD) affects many, but few show symptoms. New CFTR enhancer treatments offer hope, but their effect on CFLD and disease understanding is still being explored.
Area of Science:
- Hepatology
- Pulmonology
- Genetics
Background:
- Cystic Fibrosis-Related Liver Disease (CFLD) affects up to 40% of cystic fibrosis (CF) patients, though clinically evident disease is less common (5-10%).
- The advent of potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) enhancers has revolutionized CF treatment.
- The specific impact of these CFTR enhancers on CFLD remains largely uncharacterized.
Purpose of the Study:
- To investigate the unknown role of CFTR enhancers in the context of CFLD.
- To explore emerging questions regarding the established theories of CFLD pathogenesis.
- To highlight the evolving landscape of CFLD diagnosis and monitoring.
Main Methods:
- Review of current literature on CF, CFLD, and CFTR modulator therapies.
- Analysis of the potential mechanisms by which CFTR enhancers might influence liver disease.
- Discussion of advancements in diagnostic and monitoring technologies for CFLD.
Main Results:
- The efficacy and safety of CFTR enhancers in treating CFLD are currently unknown.
- Traditional understanding of CFLD pathogenesis is being challenged by new therapeutic approaches.
- Novel imaging technologies are improving the diagnosis and monitoring of CFLD.
Conclusions:
- CFTR enhancers represent a potential new avenue for CFLD management, though their direct impact requires further investigation.
- Re-evaluation of CFLD pathogenesis may unlock novel therapeutic strategies.
- Advancements in diagnostic tools are crucial for better patient outcomes in CFLD.
More Related Videos
Related Concept Videos
01:24Cystic Fibrosis: Management
338
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
338
01:23Cystic Fibrosis: Pathogenesis
612
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
612
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
133
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
133
01:29Chronic Pancreatitis II: Collaborative Care
206
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
206
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
382
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
382
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
107
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
107